Fulgent Genetics, Inc.
Key Metrics
- Previous Close
- $19.74
- 52-Week Range
- $13.46 – $31.04
- Market Cap
- $548.10M
- P/E (TTM)
- —
- EPS (TTM)
- -2.83
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 0.55
- PEG Ratio
- —
- Return on Equity
- -8.11%
- Return on Assets
- -6.30%
- Gross Margin
- 35.58%
- Operating Margin
- -39.35%
- Profit Margin
- -26.05%
- Current Ratio
- 6.34
- Debt/Equity
- 0.01
- Total Debt
- $9.60M
- Free Cash Flow
- $-90.90M
- Revenue Growth
- 4.40%
- Earnings Growth
- —
- Enterprise Value
- $294.22M
Market Snapshot
About
Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing services for physicians, clinicians, and patients to diagnose rare genetic disorders and enable precision medicine. The company offers a broad menu of genetic tests including single-gene testing, multi-gene panels, exome sequencing, and genome sequencing across therapeutic areas such as oncology, reproductive health, cardiology, and neurology. Fulgent significantly expanded its operations during the COVID-19 pandemic by developing and deploying widespread diagnostic testing capabilities, though the company continues to focus on its core genetic testing business. The company operates CLIA-certified and CAP-accredited laboratories utilizing advanced sequencing technologies and bioinformatics platforms.